KemPharm (KMPH) Reports Q2 Loss Per Share of $2.45

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to KemPharm (KMPH) Reports Q2 Loss Per Share of $2.45

KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results

August 13, 2015 4:05 PM EDT

Results from First of Two Intranasal Human Abuse Liability Clinical Studies Indicate KP201 Exhibits Significantly Lower Exposure to Hydrocodone When Administered Intranasally

Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET

Recent Clinical Development Highlights:

Reports positive pharmacokinetic data from first of two KP201 intranasal human abuse liability clinical trials Reported positive data from oral human abuse liability clinical trial of KP201/APAP Completed successful KP201/APAP pre-NDA meeting with FDA On track to file NDA for KP201/APAP in Q4 2015

... More